Jun 01, 2020
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
May 28, 2020
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4
Apr 08, 2020
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
Mar 12, 2020
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 06, 2020
CTI BioPharma Announces Closing of Rights Offering
Feb 14, 2020
CTI BioPharma Announces Commencement of Rights Offering
Feb 03, 2020
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
Nov 04, 2019
CTI BioPharma Reports Third Quarter 2019 Financial Results
Oct 01, 2019
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Aug 01, 2019
CTI BioPharma Reports Second Quarter 2019 Financial Results
May 29, 2019
CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
May 02, 2019
CTI BioPharma Reports First Quarter 2019 Financial Results
Apr 03, 2019
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
Mar 13, 2019
CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
Feb 20, 2019
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
Feb 11, 2019
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
Feb 01, 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Dec 28, 2018
CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
Dec 18, 2018
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
Dec 13, 2018
CTI BioPharma Announces Restructuring Plan